Mc Callion Orla
General Counsel bei ULTIMOVACS ASA
Profil
Mc Callion Orla is currently the Head of Regulatory Affairs & QA at Ultimovacs ASA since 2021.
Prior to this, he worked as the Director of Regulatory Affairs at OxThera AB from 2012 to 2021.
Dr. Orla holds a doctorate degree from Queen's University.
Aktive Positionen von Mc Callion Orla
| Unternehmen | Position | Beginn |
|---|---|---|
| ULTIMOVACS ASA | General Counsel | 01.10.2021 |
Ehemalige bekannte Positionen von Mc Callion Orla
| Unternehmen | Position | Ende |
|---|---|---|
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | General Counsel | 01.10.2021 |
Ausbildung von Mc Callion Orla
| Queen's University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ULTIMOVACS ASA | Health Technology |
| Private Unternehmen | 1 |
|---|---|
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Health Technology |
